Reduction of Tumor Growth with RNA-Targeting Treatment of the NAB2–STAT6 Fusion Transcript in Solitary Fibrous Tumor Models
暂无分享,去创建一个
J. Martín-Broto | L. Bleris | Yi Li | C. Meyer | H. Hayenga | Yi Li | J. L. Mondaza-Hernandez | D. Moura | M. Ammanamanchi | J. T. Nguyen | Zikun Zhou | Elijah F. Harbut
[1] Xuebing Wu,et al. Collateral activity of the CRISPR/RfxCas13d system in human cells , 2023, Communications Biology.
[2] Lili Cao,et al. The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model , 2023, Genome Biology.
[3] A. Kater,et al. JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL , 2022, Molecular oncology.
[4] B. Ghanim,et al. Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib , 2022, Cancers.
[5] R. Maestro,et al. ISG15 as a prognostic biomarker in solitary fibrous tumour , 2022, Cellular and Molecular Life Sciences.
[6] Shawn Hoon,et al. Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans , 2022, Nature Medicine.
[7] T. Tsukahara,et al. Development of Therapeutic RNA Manipulation for Muscular Dystrophy , 2022, Frontiers in Genome Editing.
[8] L. Roberts,et al. RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? , 2022, Frontiers in Oncology.
[9] M. Emdin,et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis , 2022, Nature Reviews Cardiology.
[10] S. Ro,et al. Current Advances in RNA Therapeutics for Human Diseases , 2022, International journal of molecular sciences.
[11] J. Blay,et al. Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond , 2022, Cancers.
[12] S. Sathyanarayanan,et al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity , 2022, Science advances.
[13] Zikang Wang,et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects , 2021, bioRxiv.
[14] W. Tarn,et al. Antisense Oligonucleotide-Based Therapy of Viral Infections , 2021, Pharmaceutics.
[15] Andrew J Want,et al. Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm , 2021, EBioMedicine.
[16] A. Abulrob,et al. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion , 2021, Expert opinion on drug metabolism & toxicology.
[17] R. Langer,et al. Nucleic Acid Delivery for Therapeutic Applications. , 2021, Advanced drug delivery reviews.
[18] D. Agostini-Vulaj,et al. Solitary fibrous tumor presenting as a colonic polyp: Report of a case and literature review , 2021 .
[19] A. Feigin,et al. Emerging therapeutics in Huntington’s disease , 2021, Expert opinion on emerging drugs.
[20] J. W. Pruitt,et al. The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy. , 2021, Orthopedic reviews.
[21] S. Crooke,et al. Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. , 2021, ACS medicinal chemistry letters.
[22] B. Davidson,et al. Gene therapy for ALS: A review , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] R. Eils,et al. Gene expression in Solitary Fibrous Tumors (SFTs) correlates with anatomical localization and NAB2-STAT6 gene fusion variants. , 2021, The American journal of pathology.
[24] Anushya Muruganujan,et al. PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API , 2020, Nucleic Acids Res..
[25] Chance M. Nowak,et al. Uncoupling gene expression noise along the central dogma using genome engineered human cell lines , 2020, Nucleic acids research.
[26] P. Rocchi,et al. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.
[27] Z. Ryoo,et al. NAB2-STAT6 fusion protein mediates cell proliferation and oncogenic progression via EGR-1 regulation. , 2020, Biochemical and biophysical research communications.
[28] Neville E. Sanjana,et al. Massively parallel Cas13 screens reveal principles for guide RNA design , 2020, Nature Biotechnology.
[29] Ansar Karimian,et al. CRISPR/Cas9 technology as a potent molecular tool for gene therapy , 2019, Journal of cellular physiology.
[30] Chance M. Nowak,et al. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. , 2019, Cell reports.
[31] Christopher E. Hart,et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.
[32] Jiansong Ji,et al. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. , 2019, Cancer letters.
[33] V. Razban,et al. Creating cell and animal models of human disease by genome editing using CRISPR/Cas9 , 2019, The journal of gene medicine.
[34] Chance M. Nowak,et al. CRISPR-Based Editing Reveals Edge-Specific Effects in Biological Networks. , 2018, The CRISPR journal.
[35] S. Konermann,et al. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors , 2018, Cell.
[36] Li Ding,et al. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers , 2018, Cell reports.
[37] G. Storm,et al. Targeting the Stat6 pathway in tumor‐associated macrophages reduces tumor growth and metastatic niche formation in breast cancer , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] T. Gant,et al. Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs , 2017, Molecular therapy. Nucleic acids.
[39] T. Tominaga,et al. Intraspinal dissemination of intracranial hemangiopericytoma: Case report and literature review , 2016, Surgical neurology international.
[40] Chance M. Nowak,et al. Guide RNA engineering for versatile Cas9 functionality , 2016, Nucleic acids research.
[41] Jeffrey T Leek,et al. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.
[42] A. Bellizzi,et al. The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing. , 2016, Cancer genetics.
[43] S. T. Bjorkman,et al. Standard loading controls are not reliable for Western blot quantification across brain development or in pathological conditions , 2016, Electrophoresis.
[44] M. White,et al. Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions , 2016, PloS one.
[45] Yi Li,et al. CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells , 2014, Nucleic acids research.
[46] Mazhar Adli,et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease , 2014, Nature Biotechnology.
[47] G. Church,et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.
[48] A. Jochemsen,et al. p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway , 2013, Cell Death and Differentiation.
[49] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[50] Seung Woo Cho,et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.
[51] Daniel Auclair,et al. Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors , 2013, Nature Genetics.
[52] K. Pienta,et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.
[53] A. Maity,et al. Molecular Neuroscience Review Article , 2011 .
[54] C. Figdor,et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. , 2011, The Journal of clinical investigation.
[55] Fermín Sánchez de Medina,et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. , 2010, Analytical biochemistry.
[56] Yun Wang,et al. Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. , 2008, Virology.
[57] M. Herlyn,et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. , 2007, Genes & development.
[58] J. Rao,et al. Solitary Fibrous Tumor , 2005, Acta Cytologica.
[59] D. Kondziolka,et al. Radiosurgery for Treatment of Recurrent Intracranial Hemangiopericytomas , 2002, Neurosurgery.
[60] B. Scheithauer,et al. Management of recurrent meningeal hemangiopericytoma , 1998, Cancer.